Enzalutamide (Xtandi®) for mHSPC. HTA ID: 21022

Assessment Status Rapid review complete
HTA ID 21022
Drug Enzalutamide
Brand Xtandi®
Indication For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
Assessment Process
Rapid review commissioned 09/06/2021
Rapid review completed 07/07/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with androgen deprivation therapy compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.